Etoperidone
An antidepressant drug
| Etoperidone | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Etoperidone is a pharmaceutical drug that was developed as an antidepressant. It belongs to the class of drugs known as serotonin antagonist and reuptake inhibitors (SARIs). Although it was never marketed in the United States, it has been used in some European countries.
Pharmacology[edit]
Etoperidone functions primarily as a serotonin antagonist and reuptake inhibitor, which means it blocks the reuptake of serotonin in the brain, increasing its availability in the synaptic cleft. This action is believed to contribute to its antidepressant effects. Additionally, etoperidone has been shown to have affinity for various neurotransmitter receptors, including alpha-adrenergic, dopaminergic, and histaminergic receptors.
Clinical Use[edit]
Etoperidone was primarily used in the treatment of major depressive disorder. Its efficacy in alleviating symptoms of depression was comparable to other antidepressants available at the time. However, due to the development of newer antidepressants with improved safety profiles and fewer side effects, etoperidone is not commonly used today.
Side Effects[edit]
The side effects of etoperidone are similar to those of other antidepressants in its class. Common side effects include drowsiness, dry mouth, and dizziness. Some patients may experience gastrointestinal disturbances such as nausea and vomiting. As with other antidepressants, there is a risk of serotonin syndrome if taken in combination with other serotonergic drugs.
Mechanism of Action[edit]
Etoperidone's mechanism of action involves the inhibition of serotonin reuptake, which increases serotonin levels in the brain. This is thought to improve mood and alleviate depressive symptoms. Additionally, its antagonistic effects on various neurotransmitter receptors may contribute to its overall therapeutic profile.
Development and History[edit]
Etoperidone was developed in the 1970s by the pharmaceutical company Angelini. It was part of a wave of new antidepressants that sought to improve upon the side effect profiles of earlier drugs. Despite its initial promise, etoperidone was overshadowed by the development of selective serotonin reuptake inhibitors (SSRIs) and other newer classes of antidepressants.
Related pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian